Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.
Theranexus colloborates with AI expert Dyliss
Latest NewsLyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
Latest NewsFollowing the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019.
Metrion Biosciences appoints Dr Andrew Southan
AppointmentsMetrion Biosciences today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Sanofi ends option phase of rare disease partnership with Alnylam
Latest NewsSanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.
Medigene AG in potential €1bn licence and R&D deal
Latest NewsTheodora Harold appointed CEO of Crescendo Biologics
AppointmentsCrescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.
AMR diagnostic specialist Gradientech raise $4.6m
Latest NewsGradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
Reaching global markets
Sponsored PublicationsSmall- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.
AgomAb Therapeutics bags €21m Series A financing
Latest NewsEuropean Biotechnology Guide in its ninth edition
Sponsored PublicationsThe 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.